Bausch + Lomb Corp's stock gained 2.04% in the last trading session, reflecting a positive market response to recent developments.
Bausch + Lomb Corp (BLCO.TO) closed at CA$21.50, marking a notable increase of 2.04% in the last trading session. This rise can be attributed to strategic advancements and promising partnerships that are enhancing the company's outlook in the ophthalmic sector.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
Bausch + Lomb Corp
BLCO.TO
BLCO.TO
Bausch + Lomb Corp
WealthAwesomeMarket cap
$8.16B
52W high
$25.70
52W low
$18.24
1W change
-5.71%
Beta
0.56
Analyst Price Targets
Based on analyst covering BLCO
Wall Street analysts forecast BLCO stock price to fall 17.6% over the next 12 months.
Consensus
BearishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$18.92
-17.6% Upside
Current Price
C$22.96
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on BLCO's historical volatility
30-Day Vol
32.9%
Annualized
90-Day Vol
31.1%
Annualized
Trend (90d)
+2.8%
Annualized drift
90d Mean
C$23.19
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$23.04 | C$20.56 โ C$25.81 |
| 60 trading days | C$23.11 | C$19.68 โ C$27.14 |
| 90 trading days | C$23.19 | C$19.05 โ C$28.23 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors should keep an eye on Bausch + Lomb's strategic initiatives, particularly its involvement with Emmecell, which could position the company favorably in the growing market for innovative eye treatments.
Bausch + Lomb Corp Market Cap Surpasses CA$7.57 Billion
With a market cap of CA$7.57 billion, Bausch + Lomb is positioned as a significant player in the healthcare sector, particularly in ophthalmology.
Bull case
The partnership with Emmecell to advance magnetic cell delivery technology is a major step for Bausch + Lomb. This collaboration could broaden its product offerings and increase its market share in eye treatments.
Bear case
Despite the positive movement, investors should be cautious. The company currently has a negative profit margin, which could impact its long-term financial health and ability to take advantage of new opportunities.
Strategic Partnerships Fuel Growth
Bausch + Lomb's recent investment in Emmecell, a company focused on innovative magnetic cell delivery technologies for ophthalmic diseases, has been a key driver behind the stock's positive performance. This partnership not only enhances Bausch + Lomb's portfolio but also aligns with the growing demand for minimally invasive treatment options in eye care.
Market Response and Investor Sentiment
The market's reaction to Bausch + Lomb's advancements reflects a broader optimism surrounding the healthcare sector, particularly in innovative treatments for eye diseases. Investors are encouraged to monitor the company's developments closely, as successful execution of its strategies could lead to sustained growth.
Advertisement
